特异性磷酸二酯酶抑制剂在风湿性左心瓣膜病肺动脉高压患者围术期的应用  

Specific Phosphodiesterase Inhibitor Application in Perioperative Period in Patients with Rheumatic Heart Valve Disease with Pulmonary Hypertension

作　　者：张竞超[1] 

机构地区：[1]郑州大学第一附属医院心外科,郑州450052

出　　处：《中国医药导刊》2014年第6期995-996,共2页Chinese Journal of Medicinal Guide

摘　　要：目的：研究特异性磷酸二酯酶抑制剂在风湿性左心瓣膜病肺动脉高压患者围术期中的应用。方法：收集我院在2011年3月~2012年3月间收治的80例风湿性左心瓣膜病肺动脉高压患者的临床资料,对其进行回顾性分析。把患者分为两组,每组各40例病例,对照组采用常规药物治疗,观察组采用特异性磷酸二酯酶抑制剂进行治疗。结果：经研究发现,观察组患者在围术期中采用特异性磷酸二酯酶抑制剂后,取得了较好的治疗效果,有39例患者安全度过围术期症状得到有效缓解,最终痊愈出院,1例患者发生不良反应。结论：特异性磷酸二酯酶抑制剂有利于帮助患者安全度过围术期,对预后具有重要意义。Objective：To study the specific phosphodiesterase inhibitor in the perioperative period in patients with rheumatic heart valve disease with pulmonary hypertension.Methods：The clinical data of 80 cases of rheumatic heart valve disease patients with pulmonary hypertension were collected in 2011 March to our hospital in 2012 March,they were retrospectively analyzed,the patients were divided into two groups, each group 40 cases,patients in the control group were given conventional drug treatment,paients in the observation group, were given specific phosphodiesterase inhibitors for treatment.Results：The study found that,the observation group were treated by specific phosphodiesterase inhibitor in the perioperative period,obtained better curative effect,39 patients survived the perioperative symptom relief,eventually recovered and discharged,1 cases of adverse reactions.Conclusion：Specific phosphodiesterase inhibitor can help the patients pass through the perioperative period safely,is of great significance to the prognosis.

关 键 词：特异性磷酸二酯酶抑制剂 肺动脉高压 

分 类 号：R654.2[医药卫生—外科学]